Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Clinical trial NCT05682755 · RECRUITING
Trial details
- NCT number
- NCT05682755
- Sponsor
- Sichuan University
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-22
- Primary completion
- 2023-12-31
- Enrollment
- 77
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.